Evidence map›Paper›PMID 25377084›Full record

ReviewCell proliferation2014

Plant natural products: from traditional compounds to new emerging drugs in cancer therapy.

L Ouyang, Y Luo, M Tian, S-Y Zhang, R Lu, J-H Wang, R Kasimu, X Li

Abstract readReview
In one paragraph

Review in Cell proliferation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Multidrug-ResistantMicroorganisms · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Understanding metabolic diversification in plants: branchpoints in the evolution of specialized metabolism.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024
    Review
  14. Article
  15. Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  16. Cytotoxicity and Multi-Enzyme Inhibition ofPlants (Basel, Switzerland) · 2024
    Article
  17. Isorhamnetin: what is theFrontiers in pharmacology · 2024
    Review
  18. Article
  19. Mini-review: research and progress of oxeiptosis in diseases.Frontiers in cell and developmental biology · 2024
    Review
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

L OuyangState Key Laboratory of Biotherapy and Department of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Y Luo
M Tian
S-Y Zhang
R Lu
J-H Wang
R Kasimu
X Li

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural products are chemical compounds or substances produced naturally by living organisms. With the development of modern technology, more and more plant extracts have been found to be useful to medical practice. Both micromolecules and macromolecules have been reported to have the ability to inhibit tumour progression, a novel weapon to fight cancer by targeting its 10 characteristic hallmarks. In this review, we focus on summarizing plant natural compounds and their derivatives with anti-tumour properties, into categories, according to their potential therapeutic strategies against different types of human cancer. Taken together, we present a well-grounded review of these properties, hoping to shed new light on discovery of novel anti-tumour therapeutic drugs from known plant natural sources.

Indexed as

Antineoplastic Agents, PhytogenicBiological ProductsCell SurvivalFemaleHumansNeoplasmsPlant ExtractsPlantsSignal TransductionAntineoplastic Agents, PhytogenicBiological ProductsPlant Extracts

Identifiers

PMID25377084
PMCPMC6496831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.